Background-Percutaneous coronary interventions in patients with chronic kidney disease have shown suboptimal results. Drug-eluting stents (DES) might reduce the rate of target vessel revascularization in comparison with baremetal stents (BMS) in patients with chronic kidney disease. However, given the multiple concomitant individual variables present in such patients, the comparison of neointimal growth after percutaneous coronary intervention is complex and difficult to assess.
P atients with chronic kidney disease (CKD) requiring myocardial revascularization represent a challenging group often affected by multivessel disease and complex coronary lesions. 1 Percutaneous coronary intervention (PCI) in patients with CKD has shown suboptimal results in comparison with surgery, especially in patients without a need for permanent dialysis. [2] [3] [4] [5] [6] [7] Post hoc analyses from randomized clinical trials and large registries showed that first-generation drugeluting stents (DES), in comparison with bare-metal stents (BMS), reduced the restenosis rate in patients with CKD. 8, 9 Simsek et al 10 reported no superiority of both paclitaxel-and sirolimus-eluting stents over BMS in safety and efficacy end points in all-comer PCI patients with CKD at long-term follow-up. The lack of dedicated randomized trials comparing new-generation DES and BMS in patients with CKD remains a well-known limitation of currently available evidence.
Notably, in patients with CKD, multiple concomitant individual factors, including inflammatory and procoagulant mediators, oxidative stress, comorbidities, and medical treatment, may be responsible for neointimal hyperplasia and thrombosis after coronary stenting, thus making difficult the comparison of different therapeutic strategies in different patient groups. [11] [12] [13] The Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) is a prospective, randomized, multicenter, spontaneous study aimed to directly compare the efficacy of everolimus-eluting stent (Xience V, Abbott Vascular Company, Abbott Park, IL) and its BMS counterpart with an identical design, the Multi-Link Vision stent (Abbott Vascular Company), in the prevention of clinical restenosis, both implanted in the same patient with multivessel coronary artery disease and CKD. This study model allows obviation for the multiple and unpredictable potential baseline differences of this complex population.
Methods
The rationale and study design of the RENAL-DES trial have been reported elsewhere. 14 In brief, the aim of the study was the comparison of the need for repeated ischemia-driven target vessel revascularization (ID-TVR) of Xience V or Multi-Link Vision stents in consecutive patients with CKD receiving both types of stents for at least 2 significant coronary lesions in 2 major epicardial vessels, by randomizing for coronary vessel (each patient being its own comparator). This intraindividual design has been previously validated in diabetic patients with multivessel coronary artery disease undergoing multiple PCI. 15 The study protocol and related materials were approved by the institutional review boards and ethical committees of all participating centers. The protocol was attributed at http://clinicaltrials.gov, Unique identifier: NCT 00818792.
Patient Selection and Procedure for Randomization
Between January 2009 and February 2012, all consecutive patients with an estimated glomerular filtration rate <60 mL/min (assessed with the Cockcroft-Gault formula) 16 undergoing coronary angiography for symptoms or signs of myocardial ischemia and showing at least 2 significant coronary lesions amenable to PCI in at least 2 epicardial vessels were considered eligible for enrolment. In the presence of intermediate stenoses without evidence of preprocedural inducible ischemia, a fractional flow reserve was performed as previously described, 17 and PCI was physiologically guided in the case of a fractional flow reserve ≤ 0.80. CKD was defined as moderate (estimated glomerular filtration rate, 30-59 mL/min) and severe CKD and kidney failure (estimated glomerular filtration rate, <30 mL/min), according to published guidelines. 18 The exclusion criteria for this study were as follows: (1) age <18 or >85 years, (2) presence of left main coronary artery disease, or other angiographic indication to coronary artery bypass grafting by consensus of the Heart Team, (3) in-stent restenosis, (4) saphenous vein graft disease, (5) ST-segment elevation myocardial infarction (<3 days), (6) vessel diameter <2.5 or >4 mm, (7) contraindication to long-term dual-antiplatelet therapy, (8) complete functional revascularization not achievable by PCI as defined by others, 19 (9) severe valvular heart disease, and (10) childbearing potential.
For the prevention of contrast-induced nephropathy, all patients were treated according to standard protocols, 14 as recommended by current guidelines 20 (see online-only Data Supplement). Patients undergoing diagnostic coronary angiography because of stable or acute coronary syndromes and showing multivessel disease were jointly evaluated in each institution by a heart team, composed of a cardiac surgeon, an interventionalist, and a clinical cardiologist.
The final decision of patient enrolment was made after a comprehensive review of all relevant factors, including a nephrology consultation, when appropriate. The informed consent was always obtained after the diagnostic catheterization and before randomization. Current recommendations for ad hoc or deferred PCI were applied. 20 After the guidewire had crossed the lesion, patients were randomly assigned to receive Xience V and Multi-Link Vision with the use of sealed envelopes containing a centralized computer-generated randomization sequence for coronary vessel (left anterior descending or left circumflex or right coronary artery). The same stent (Xience V or Multi-Link Vision) was used for the treatment of multiple lesions in the same vessel (if possible, a single long DES was used, whereas a spot stenting strategy was preferred with BMS). For patients with 3-vessel disease requiring the implantation of other stents, the type of stent implanted in the remaining vessel was also randomized by using the same computer-generated randomization sequence for coronary vessel.
Coronary Angiogram, Quantitative Coronary Angiography, and PCI Procedure
Baseline, postprocedural, and follow-up coronary angiograms were digitally recorded and assessed off-line in a quantitative coronary angiography core laboratory (NBR Core Laboratory, Verona, Italy), with the use of previously validated methodology. 21 All measurements were performed on cineangiograms recorded after the intracoronary administration of nitroglycerin in at least 2 orthogonal views that demonstrate the target lesion free of foreshortening or vessel overlap.
PCI was performed via a 6F or 7F sheath in the femoral or radial artery, according to standard practice. Procedural success was defined as an angiographic residual diameter stenosis <20% (visual estimation), without the occurrence of cardiac death, Q-wave or non-Qwave myocardial infarction, or repeat revascularization of the target vessel during the hospital stay. The implantation of multiple overlapping coronary stents was allowed in the case of incomplete lesion coverage, and endoluminal injury requiring additional stent coverage beyond the margins of the initial stent deployed. In the case of stent implantation failure, the patient was excluded from the study.
During the procedure, patients received intravenous boluses of heparin in sufficient doses to prolong the activated clotting time (≥250 s). Periprocedural antithrombotic therapy consisted of aspirin at standard dosages and clopidogrel at a loading dose of 300 mg. The use of platelet glycoprotein IIb/IIIa inhibitors was left to the operator's discretion. Following the procedure, patients continued to receive daily lifelong aspirin plus clopidogrel 75 mg a day for 12 months. 22 In addition, patients received anti-ischemic therapy (β-blockers, calcium antagonists, and nitrates, alone or in combination); angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers for hypertension, reduced ejection fraction, or secondary prevention; and low-density lipoprotein cholesterol-lowering therapy with statins alone or in combination with ezetimibe to achieve a target of 60 to 85 mg/dL. After achievement of the low-density lipoprotein target, secondary targets were raising high-density lipoprotein cholesterol >40 mg/dL and lowering triglyceride levels <150 mg/dL with exercise or in combination with extended-release niacin or fibrates. Lifestyle counseling for diet, smoking cessation, glycemic control, and weight loss was also administered, according to current guidelines. 
Follow-Up
Following randomization, all patients were subject to complete clinical follow-up. Telephone-based interviews and office-based direct visits were performed at 30 days and 12 months, respectively, for end-point adjudications. If any event occurred during the study period, full documentation of hospital admission (with any invasive and noninvasive procedure results) was provided and evaluated by an independent committee (see Appendix in the online-only Data Supplement). Stress and rest gated thallium 201 (Tl-201) myocardial single-photon emission computed tomography (SPECT) was performed between 9 and12 months after the index procedure unless recurrent ischemic symptoms required earlier repeat coronary by guest on July 24, 2017 http://circ.ahajournals.org/ Downloaded from angiography. Repeat coronary angiography was performed in the case of the recurrence of ischemic symptoms and evidence of ischemia in at least one of the treated regions at Tl-201 myocardial SPECT (see Figure I in the online-only Data Supplement).
Myocardial SPECT data were stored electronically at the treatment vessel site and sent to the nuclear core laboratory (Etisan, Rome, Italy) for imaging interpretation by nuclear cardiologists blinded to the site and randomization arm. The degree of myocardial perfusion was assessed in 20 myocardial segments, 24 grouped into 6 regions according to the anatomic distribution of the coronary vascular territories: apical, anterior and septal (left anterior descending), posterior (left circumflex), inferior (right coronary), and lateral, as extension of posterior or inferior regions (circumflex or right coronary territory, respectively). Semiquantitative 6-region visual interpretation was performed by consensus of 2 experienced observers using a 5-point scoring system (0, normal; 1, equivocal; 2, moderate; 3, severe reduction in Tl-201 uptake; and 4, absence of detectable tracer uptake). The summed stress and rest scores were obtained by adding the scores of the 6 regions of the respective images. The sum of the differences between each of the 6 regions from these images was defined as the summed difference score, representing the amount of ischemia. A summed difference score >1 in each region was indicative of ischemia.
End Points
The primary end point of the study was ID-TVR at 12 months defined as revascularization procedure (repeat PCI or coronary artery bypass surgery) in the target coronary vessel associated with any of the following: (a) evidence of ischemia in the treated region at Tl-201 myocardial SPECT, (b) ischemic symptoms requiring coronary angiography, and (c) an angiographic diameter restenosis ≥50% at quantitative coronary angiography.
Secondary end points of the study were the incidence of cardiac death and PCI-related vessel myocardial infarction, stent thrombosis, target lesion revascularization, and TVR at 30 days and 12 months. All deaths were considered cardiac unless an unequivocal noncardiac cause could be established. Spontaneous myocardial infarction after the periprocedural period 25 was defined as either the development of pathological Q waves lasting at least 0.4 s in at least 2 contiguous leads with an elevation of the creatine kinase-MB fraction level or, in the absence of pathological Q waves, an elevation in creatine kinase-MB fraction levels to >3 times the upper reference limit alone. Target lesion revascularization was defined as repeated revascularization because of a coronary stenosis of at least 50% of the luminal diameter anywhere within the stent or within the 5-mm borders proximal or distal to the stent.
Statistical Analysis
The size of the sample was calculated by using the McNemar test for comparison of dependent proportions to achieve 80% statistical power at a significance level of 0.05. Calculations were based on previous not-randomized reports of ≈20% of clinical restenosis (ID-TVR) at 12 months in patients with CKD treated with BMS implantation, 8, 9 with an expected reduction by DES to 10% and an occurrence of intrapatient multilesion restenosis of 2%. 26 Assuming a 10% dropout rate, a goal of 213 patients (426 treated vessels) was set. Because 20% of the patients would require stent implantation in 3 vessels, we expected to analyze ≈500 treated vessels.
Comparisons of the continuous or discrete variables between stent groups (Xience V and Multi-Link Vision) have been performed by using a paired t test or a McNemar test, respectively. Continuous or discrete variables between patients groups (those treated on 2 or 3 coronary vessels) were compared by unpaired t test or χ 2 test, respectively. To investigate the independent predictors of ID-TVR at 12 months, a regression analysis with a random-effects model (with the use of the type of vessel as a random factor) has been performed by a mixed-model analysis module in the IBM SPSS 20.0 stat package and confirmed by glmer function in R open source stat package. All variables known to be relevant for the study end point (type of stent, target vessel, lesion location, lesion type, vessel size, stent length, baseline minimal lumen diameter, and stenosis) were entered into the model. A probability value ≤0.05 (2-tailed) was considered significant. Analysis was performed with IBM SPSS 20.0 software and R open source statistical package. Results are expressed as mean±standard deviation, unless otherwise specified.
Results
During the study period, 415 consecutive patients with CKD met inclusion criteria. Of these, 126 (30.4%) underwent surgical revascularization, 31 (7.5%) were treated with pharmacological therapy, and 43 (10.4%) presented a coronary anatomy not suitable for complete revascularization by PCI according to a joint evaluation by the Heart Team ( Figure 1) . The remaining 215 patients (51.8%) were enrolled in the study and randomly assigned to receive both a Xience V and a Multi-Link Vision in different coronary arteries. A total of 512 coronary vessels were successfully treated with stent implantation (2.4±0.4 vessels treated per patient): 257 assigned to Xience V and the remaining 255 assigned to Multi-Link Vision (2.9±1.1 stents per patient).
Clinical characteristics and pharmacological therapy at the time of enrollment are summarized in Table 1 . The mean age of the study population was 73 years; a high proportion of patients presented a 3-vessel disease (42%), acute coronary syndromes (57%), and diabetes mellitus (44%). The mean estimated glomerular filtration rate was 46.8 mL/min (range, 7-59 mL/min) and 10% were on dialysis.
The baseline angiographic characteristics of the treated coronary vessels and procedural variables are displayed in Table 2 . A total of 628 stents (318 Xience V and 310 Multi-Link Vision) have been implanted on 607 coronary lesions (306 and 301 treated with DES or BMS, respectively). Lesion type, reference vessel diameter, pre-and postprocedural minimal lumen diameter, and diameter stenosis percentage at angiography were similar in both groups. Stent postdilation, total stent length, and number of stents per treated vessel were higher in the DES group, whereas the rate of direct stenting and final stent diameter were higher in the BMS group (Table 2) , according to different procedural strategies usually preferred with DES or BMS implantation. 27 In all patients, iopamidol (Iopamiro 370 mg/mL, Bracco Imaging Italia s.r.l., Italy) was used as contrast agent, at a median dose of 215 mL per patient; 5 (2.3%) patients exhibited a renal function deterioration requiring hemodialysis during hospitalization.
Twenty patients (9.3%) underwent coronary angiography before the 12-month follow-up because of symptom recurrence. One hundred ninety-five patients (90.7%) underwent the scheduled SPECT 9 to 12 months after the index PCI. Among these, 16 (8.2%) underwent coronary angiography for signs of ischemia in the treated regions at Tl-201 myocardial SPECT; a significant stent restenosis was detected in 14 (87.5%) patients.
Clinical Outcomes at Follow-Up
Clinical events at 1 and 12 months in the overall population are shown in Table 3 . At 1 month, 1 patient had a myocardial infarction attributable to subacute stent thrombosis of a Multi-Link Vision stent that required emergency target lesion revascularization 4 days after the index PCI.
Clinical follow-up was obtained at 12 months (11.8±2.1 months) in all patients: 8 (3.7%) patients died, 3 of them for cardiac reasons. One additional patient required dialysis, and no case of late stent thrombosis occurred. TVR was performed in 32 (14.8%) patients on 44 coronary lesions: 33 (13%) on the BMS-treated lesions, and 11 (4.3%) on the DES-treated lesions (P=0.001); accordingly, the target lesion revascularization rate was 13% (28 patients), performed on 41 coronary lesions: 34 (13.4%) on the BMS-treated lesions and 7 (2.7%) on the DES-treated lesions (P=0.001) ( Table 3) .
The incidence of ID-TVR at 12 months (primary end point) was significantly higher in BMS (11.4%; 95% confidence interval [CI], 7.8%-16%) in comparison with the DES group (2.7%; 95% CI, 1.1%-5.6%), respectively (P<0.001) ( Figure 2) ; accordingly, ischemia-driven target lesion revascularization was higher in the BMS than in the DES group (11.4% versus 1.2%, P<0.001). Among the 26 patients who received an ID-TVR at follow-up, 3 (11.5%) needed coronary artery bypass grafting, and the remaining 23 (88.5%) were treated with PCI by using another DES or conventional balloon angioplasty in almost all lesions. The incidence of the primary end point was consistently higher in the BMS than in the DES group among patients treated on 2 coronary vessels (9.1%; 95% CI, 4.2%-13.9% versus 1.5%; 95% CI, 0.5%-3.5%; P<0.001, respectively) and with diabetes mellitus (6.7%; 95% CI, 1.9%-11.5% versus 1.7%; 95% CI, 0.6%-4.0%; P<0.001, respectively).
In addition, the different ID-TVR rate in favor of DES in comparison with BMS was consistent among different grades of renal dysfunction. Indeed, among 161 patients (74.8%) with moderate CKD treated on 384 coronary vessels, the ID-TVR rate was 2.6% and 7.3%, P=0.03, respectively. Among 54 patients (25.2%) with severe CKD or patients on dialysis, treated on 126 coronary vessels, the ID-TVR rate remained significantly lower in the DES than in the BMS group (3.1% versus 24.2%, P=0.005) (Figure 2 ).
Multivariate analysis yielded 2 independent predictors of ID-TVR at 1 year: BMS implantation (odds ratio, 4.95; 95% CI, 2.1-11.6; P<0.001) and vessel size (odds ratio, 0.32; 95% CI, 0.1-0.7; P=0.006) ( Table 4) .
Discussion
This is the first randomized trial showing a beneficial effect in terms of clinical restenosis of a new-generation DES in comparison with its BMS counterpart in patients with multivessel coronary artery disease and CKD with an identical biochemical milieu, as established by the specific intrapatient comparison model of this study.
The principal findings of the study could be summarized as follows: (1) the performance of the Multi-Link Vision BMS is remarkable despite the known unfavorable context that CKD represents for PCI; (2) the second-generation everolimus-eluting stent Xience V reduces significantly the recurrence of myocardial ischemia at 1 year and the subsequent need for reinterventions in comparison with BMS. This difference is strictly attributable to the fluoro-polymer coverage and the elution of everolimus, because both the metallic alloy composition and the geometric structure of the stents are identical; (3) the efficacy of the everolimus-eluting Xience V stent in preventing restenosis is independent of the severity of CKD, including the most unfavorable setting of permanent replacement therapy.
The good performance of BMS in our study may be related to the commitment of the investigators in respecting the best standards of practice for stenting, as reflected by the use of shorter and larger stents in the BMS group, and the use of new-generation stents, as well, that, being those with the thinnest stent struts, cause less neointimal hyperplasia. 27 Furthermore, compliance to optimal medical therapy during follow-up is also a determinant variable of the Values are mean±SD or number (percentage of total). ACE indicates angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; ACS, acute coronary syndrome; CAD, coronary artery disease; CABG:, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, heart rate; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; and SD, standard deviation.
*Comparisons of the continuous or discrete variables between patient groups have been performed by using unpaired t test or χ 2 test, respectively. †Obesity was defined as body mass index ≥30. ‡Dyslipidemia was defined as a total cholesterol concentration >5.69 mmol/L, a triglyceride concentration >1.69 mmol/L, an HDL cholesterol concentration <1.03 mmol/L, and having received treatment for dyslipidemia.
§Among the 204 patients alive at follow-up.
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http://circ.ahajournals.org/ Downloaded from long-term clinical success of PCI, regardless of the type of stent implanted. As to the DES performance, our findings confirm and expand those obtained in previous investigations with first-generation DES in patients with mild to moderate CKD. 8, 9, 28, 29 Indeed, a post hoc analysis from the TAXUS-IV trial showed that paclitaxel-eluting stent, in comparison with BMS, reduces restenosis at 1 year in patients with renal dysfunction. 8 Similar results were obtained by another post hoc analysis from the SIRIUS trial, showing a reduced 5-year restenosis rate with sirolimus-eluting stents in comparison with BMS. 9 On the contrary, a recent pooled analysis from Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries showed no superiority of both types of DES over BMS in safety and efficacy end points for patients with impaired renal function at 6-year follow-up. 10 However, the retrospective nature of that study, in which first-generation DESs were used, does not allow a direct comparison with our findings obtained at a shorter follow-up time. In addition, all these findings refer to patients with mild to moderate renal insufficiency, because patients with severe or end-stage CKD were excluded. [8] [9] [10] Arguably, these patients constitute one of the highest-risk groups in terms of efficacy of coronary revascularization procedures. Recently, Shroff et al, 30 using the United States Renal Data System database, showed that the probability of repeat revascularization accounting for the competing risk of death was 18% with BMS and 19% with DES at 1 year, among >23 000 dialysis patients undergoing coronary revascularization. Accordingly, in a recent analysis from the National Cardiovascular Data Registry CathPCI registry among CKD and patients >65 years of age, there appeared to be a differential reduction in revascularization rates for DES in comparison with BMS (interaction P<0.01) in patients with normal renal function only, whereas patients with mild, moderate, or severe CKD and patients on dialysis did not show significant differences. 31 It is worth noting that, in our study, the efficacy in terms of clinical restenosis of a new-generation DES is preserved even in patients with severe CKD. Such findings are reinforced by the use of an intraindividual design, previously validated in other studies on multivessel patients undergoing PCI aimed to evaluate the angiographic or clinical performance of coronary stents. 15, 32, 33 All these studies suggested that this comparison design may allow the obviation of the multiple and unpredictable baseline differences in high-risk populations, including patients with acute coronary syndrome who have thrombotic burden and nonculprit lesions. According to this particular study protocol, both Xience V and Multi-Link Vision stents were implanted in the same patient for at least 2 significant coronary lesions in 2 major epicardial vessels, by randomizing for coronary vessels. Thus, our findings also show that the superiority of Xience V to BMS is independent of all specific biochemical and clinical features of the CKD patients. Moreover, we found that BMS was an independent predictor of clinical restenosis, which was almost 5 times higher than in DES-treated vessels. Remarkably, in patients with CKD, coronary restenosis resulting from neointimal hyperplasia is a very complex process influenced by several pathophysiological mechanisms, including vascular inflammation, increase of calcification promoters, and the activation of the renin-angiotensin system with consequent enhanced production of reactive oxygen species. [11] [12] [13] Indeed, CKD promotes hypertension and dyslipidemia, which together with diabetes mellitus are important risk factors for the development of endothelial dysfunction and progression of atherosclerosis. [11] [12] [13] Finally, a variety of individual features, such as creatinine and GFR control over the time, associated medical treatments, and response to treatment, might contribute to the accelerated atherosclerosis observed in these patients. [11] [12] [13] The role played by all these mechanisms may also vary among different CKD patients, rising in magnitude as the severity of CKD increases. The particular design of our study permitted an adjustment of the obtained results for all these variables. Nevertheless, the present intraindividual design precludes any comparison between different coronary stents in terms of major clinical end points, and it is still unknown whether it provides similar results to interindividual studies. Indeed, the impact of lesion-specific factors on outcome in our population cannot be completely assessed because a lesion characterization by intravascular devices instead of angiographic evaluation was not routinely performed. In addition, operators were The death rate and stent thrombosis observed at 1 year in our study were lower than previously reported. 8, 9, 28, 29 This may be explained by the relatively short duration of the follow-up and the prospective nature of our study in which each patient was systematically treated for the prevention of contrast-induced nephropathy, the optimal medical treatment achieved in almost all patients, and the use of new-generation DES and BMS. Finally, our findings refer to ≈50% of patients with CKD and multivessel coronary artery disease in whom a complete myocardial revascularization could be achieved by PCI; therefore, they cannot be applied to all CKD patients with multivessel coronary artery disease.
Conclusions
This is the first randomized trial showing a beneficial effect in terms of clinical restenosis of a new-generation DES in comparison with a BMS of equal design, in patients with multivessel coronary artery disease and CKD. Long-term data will clarify whether these favorable results are maintained over time and the relative impact of plaque progression in this high-risk population.
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SUPPLEMENTAL METHODS

Biochemical determinations
Besides routine determinations, blood samples for creatinine and cystatin C serum levels 1S, 2S has been obtained at admission, 3-5 days, 30 days, and at 9 and 12 months, except in patients in dialysis. Troponin I (ng/mL), CK-MB and C-reactive protein levels has been determined at admission, 6 and 24 hours after PCI and at discharge.
Blood cell counting with formula, glycemia and urinary protein values has been also verified all patients during hospitalization, at 30 days, and at 9 and 12 months.
Prevention of contrast induced nephropathy
For the prevention of contrast induced nephropathy all patients has been treated according to the following protocols:
3S-6S a) Patients at high risk (creatinine clearance ≤30 ml/min): 1) 0.9% Saline solution:
• 1 ml/Kg/h for 24 hours (to be started 12 hours before the procedure)
• reduce to 0,5 ml/Kg/min if ejection fraction ≤0.45 or NYHA class ≥II 2) 0.84% Sodium bicarbonate:
• Bolus: ml/h= body weight in Kg x 0,462 mEq (for 60 minutes)
• IV infusion: ml/h=(body weight in Kg x 0,154 mEq)/6 (for 6 hours)
3) N-Acetylcysteine:
• 600 mg per os BID (the day before and the day scheduled for procedure) b) Patients at moderate-low risk (creatinine clearance 31-60 ml/min): 1) 0.9% Saline solution:
• 1 ml/Kg/h for 24 hours (to be started 12 hours before the procedure) S3
• reduce to 0,5 ml/Kg/min if ejection fraction ≤0.45 or NYHA class ≥II 2) N-Acetylcysteine:
• 600 mg per os BID (the day before and the day scheduled for procedure). Figure 1S . Example of a patient with renal dysfunction and two-vessel coronary artery disease enrolled in the RENAL-DES study. After randomization, this patient was treated with two Xience-V on left circumflex and one Vision on left anterior descending. Seven months after stent implantations, he experienced a recurrence of angina and underwent a coronary angiography that documented a significant and diffuse restenosis of the bare-metal stent.
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